Skip to content
OpenCapital
Get started

Oruka Therapeutics, Inc. ORKA Share-based compensation expense related to employee stock plans

Share-based compensation expense related to employee stock plans at other companies

Insmed logo
InsmedINSM
——

Other financials

Income statement

See full
Revenue-—
Operating income-$36.4M-45.2%
Net income-$31.8M-51.5%
EPS (diluted)-$0.46+93.4%

Balance sheet

See full
Cash & equivalents$49.5M-40.7%
Total debt$1.8M+90.8%
Total equity$486.7M+33.4%
Total assets$504.5M+33.8%

Cash flow

See full
Operating cash flow-$23.6M-13.0%
CapEx$73.0K+462%
Free cash flow-$23.7M-13.3%

Valuation

See full
Market cap$5.03B+533%

Returns & leverage

See full
Return on equity-27.3%-11.1pp
Debt / equity0×0.0×
Current ratio23.8×-6.3×

Where this comes from

Reported directly by Oruka Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue.

The official record: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Oruka Therapeutics, Inc.'s share-based compensation expense related to employee stock plans.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Oruka Therapeutics, Inc.'s share-based compensation expense related to employee stock plans?
Oruka Therapeutics, Inc. (ORKA) reported share-based compensation expense related to employee stock plans of $6.97M in Q1 2026.
How has Oruka Therapeutics, Inc.'s share-based compensation expense related to employee stock plans changed year-over-year?
Oruka Therapeutics, Inc.'s share-based compensation expense related to employee stock plans increased by 100.9% year-over-year, from $3.47M to $6.97M.